Literature DB >> 12557270

Selegiline potentiates cocaine-induced increases in rodent nucleus accumbens dopamine.

Wynne K Schiffer1, Manijeh Azmoodeh, Madina Gerasimov, Nora D Volkow, Joanna S Fowler, Stephen L Dewey.   

Abstract

Selegiline has been proposed as a treatment for cocaine addiction and studies in humans suggest that it attenuates cocaine's reinforcing effects. Here we assessed the effects of selegiline treatment on cocaine-induced increases in nucleus accumbens (NAc) dopamine (DA) in freely moving rodents. Chronic treatment with selegiline (L-deprenyl, 0.25/mg/kg, 24 days) potentiated cocaine-induced increases in NAc DA from 350-600%. However, this enhanced response was abolished when animals were treated chronically with both cocaine and selegiline. Inasmuch as increases in NAc DA are associated with the reinforcing effects of cocaine, these results obtained in rodents suggest that MAO-A and -B inhibition may not be a suitable strategy to antagonize cocaine's reinforcing effects during cocaine detoxification. On the other hand, chronic selegiline treatment may improve DA deficits, which are thought to contribute to relapse through a decreased response to natural rewards. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557270     DOI: 10.1002/syn.10183

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  10 in total

Review 1.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

2.  Evidence that sleep deprivation downregulates dopamine D2R in ventral striatum in the human brain.

Authors:  Nora D Volkow; Dardo Tomasi; Gene-Jack Wang; Frank Telang; Joanna S Fowler; Jean Logan; Helene Benveniste; Ron Kim; Panayotis K Thanos; Sergi Ferré
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

3.  The role of catecholamines in HIV neuropathogenesis.

Authors:  R Nolan; P J Gaskill
Journal:  Brain Res       Date:  2018-04-27       Impact factor: 3.252

4.  The effect of nicotine in combination with various dopaminergic drugs on nigrostriatal dopamine in rats.

Authors:  Sanna Janhunen; Paula Mielikäinen; Päivi Paldánius; Raimo K Tuominen; Liisa Ahtee; Seppo Kaakkola
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-07-13       Impact factor: 3.000

Review 5.  Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND.

Authors:  Peter J Gaskill; Tina M Calderon; Jacqueline S Coley; Joan W Berman
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-01       Impact factor: 4.147

6.  A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers.

Authors:  Andrea H Weinberger; Erin L Reutenauer; Peter I Jatlow; Stephanie S O'Malley; Marc N Potenza; Tony P George
Journal:  Drug Alcohol Depend       Date:  2009-11-24       Impact factor: 4.492

7.  Dopamine activates NF-κB and primes the NLRP3 inflammasome in primary human macrophages.

Authors:  R A Nolan; K L Reeb; Y Rong; S M Matt; H S Johnson; K Runner; P J Gaskill
Journal:  Brain Behav Immun Health       Date:  2019-12-31

8.  A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.

Authors:  Debra S Harris; Thomas Everhart; Peyton Jacob; Emil Lin; John E Mendelson; Reese T Jones
Journal:  BMC Clin Pharmacol       Date:  2009-08-01

9.  Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse.

Authors:  Peter J Gaskill; Loreto Carvallo; Eliseo A Eugenin; Joan W Berman
Journal:  J Neuroinflammation       Date:  2012-08-18       Impact factor: 8.322

10.  PKG1α oxidation negatively regulates food seeking behaviour and reward.

Authors:  Celine Duraffourd; Robert T R Huckstepp; Ingke Braren; Cathy Fernandes; Olivier Brock; Alessio Delogu; Oleksandra Prysyazhna; Joseph Burgoyne; Philip Eaton
Journal:  Redox Biol       Date:  2018-12-18       Impact factor: 11.799

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.